| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 11,915 | 12,613 | ||
| General and administrative | 3,586 | 3,711 | ||
| Total operating expenses | 15,501 | 16,324 | ||
| Loss from operations | -15,501 | -16,324 | ||
| Interest income | 804 | 934 | ||
| Interest and other expense | 2 | - | ||
| Total other income and (expense) | 802 | 934 | ||
| Net loss and comprehensive loss | -14,699 | -15,390 | ||
| Earnings per share, basic, total | -1.09 | -1.14 | ||
| Net loss per share attributable to common stockholders, diluted | -1.09 | -1.14 | ||
| Weighted average number of shares outstanding, basic, total | 13,530,892 | 13,509,080 | ||
| Weighted average number of shares outstanding, diluted | 13,530,892 | 13,509,080 | ||
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)